MIB E3 ubiquitin protein ligase 2Genealiases: ZZANK1 · ZZZ5
Q-omics provides the consensus-scored MIB2 profile across patient tissues and cancer cell-line models. MIB2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MIB2 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, MIB2 RNA expression shows 18,540 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, HNSC, and ACC as cancer lineages where MIB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIB2 survival associations across molecular data types. MIB2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIB2 RNA expression–survival associations across cancer types. High MIB2 expression shows unfavorable associations in ACC, KICH, LGG and LIHC, but favorable associations in UVM and CHOL. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MIB2 RNA expression.
This table summarizes MIB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MIB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIB2 shows lower tumor expression in KICH and higher tumor expression in HNSC, COAD, KIRC, STAD and LIHC. The HNSC box plot shows higher MIB2 RNA expression in tumor versus normal tissue (log2 FC = +0.548, t-test p < 0.001).
This table shows molecular features associated with MIB2 in patient tissues and cancer cell lines. In patient samples, MIB2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MIB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
